Helper molecules act as ‘chaperones’ to protect brain cells in fight against ALS and frontal lobe dementia

Researchers have identified specialized molecules that can keep a key protein from forming the toxic clumps associated with ALS and frontotemporal dementia (frontal lobe dementia), suggesting a potential new way to protect brain cells.

The study, published in Science, shows that short strands of RNA can act as molecular “chaperones,” helping guide and stabilize the protein TDP‑43 and reducing the abnormal behavior that helps drive these neurodegenerative diseases. Computer simulations performed at Texas A&M University helped explain how these molecules reshape the protein at the molecular level.

What goes wrong in ALS and frontal lobe dementia

TDP‑43 is a protein that helps regulate RNA, molecules that carry genetic instructions within cells. But in ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease) and frontotemporal dementia, it can move out of its proper location and form clumps that disrupt normal cell function and contribute to neuron damage.

Preventing those clumps — or reversing them — has become a major focus for researchers studying these diseases.

This new study identifies short RNA molecules, called “RNA chaperones,” that help guide TDP‑43 into forms that are less likely to clump and more likely to function properly.

Simulations reveal how the molecules work

While experiments showed that these RNA chaperones reduce TDP‑43 clumping, how it worked was difficult to observe directly. That’s where computer simulations led by Dr. Jeetain Mittal, professor of chemical engineering and chemistry at Texas A&M, played a key role.

Using detailed molecular simulations, the team found that the molecules don’t act by blocking the most problematic part of the protein directly. Instead, they bind elsewhere and trigger a broader shift in how the protein folds and interacts with itself.

“What was exciting to us was that the simulations showed the molecules don’t have to attach directly to the part of the protein that causes problems,” Mittal said. “Instead, they bind to another region and shift how the whole protein is organized, making it less likely to form harmful clumps.”

From unexpected result to confirmed finding

The discovery didn’t start as a coordinated effort; rather, it began as an unexpected result within Mittal’s group. It came together, Mittal explains, through a collaboration with Dr. James Shorter at the University of Pennsylvania.

“When my student first showed me these results, I was skeptical,” he said. “The effect was unexpected, and my first thought was that perhaps the simulations were not fully converged. Later, when Jim Shorter’s group reached out with experimental results pointing in a similar direction, it became clear that the simulations were capturing something real.”

The collaboration came together through Dr. Nicolas Fawzi, a professor of molecular biology, cell biology and biochemistry at Brown University, long-time collaborator of Mittal and co-author on the study, who connected the A&M group with the Penn team.

How simulations and experiments come together

The study combined experimental, biophysical and computational approaches to better understand how these RNA chaperones work.

“This is a nice example of how science often works,” Mittal said. “The experimental results were the driving force of the study, but simulations helped us see how the pieces could fit together at the molecular level. The fact that independent computational and experimental observations converged on the same mechanism made the story much stronger.”

The simulations showed that these RNA chaperones make the protein more stable by changing how its parts interact, instead of just blocking one problem spot.

Why this matters for future research

The team’s findings suggest a different way to approach diseases like ALS and frontotemporal dementia: instead of trying to eliminate harmful proteins, researchers may be able to shift them into safer, more stable forms.

“These proteins are dynamic and challenging to study with just one approach,” Mittal said. “Simulations let us see how a change in one part of the protein affects the rest of it. That kind of insight helps us better understand the biology and could eventually guide new treatment strategies.”

While more work is needed to translate these findings into treatments, the study offers early evidence that RNA chaperones could be developed as tools to counter the toxic behavior of TDP‑43.

A new direction for studying disease-linked proteins

By stabilizing TDP‑43 in forms that resist clumping, these RNA chaperones highlight a promising direction for future research into neurodegenerative disease.

“Rather than targeting a single site on a protein, this work points to a broader strategy,” Mittal said, “reshaping how a protein behaves across its entire structure to reduce the damage associated with ALS and frontotemporal dementia.

“Undoubtedly, the hope here is we are finding new ways to help patients who are living with these devastating diseases.”

This research was funded by the National Institutes of Health, National Science Foundation, Alzheimer’s Association, American Heart Association, UK Dementia Research Institute, Office of the Assistant Secretary of Defense for Health Affairs and more. The research team includes Texas A&M, University of Pennsylvania, University of Pittsburgh, Brown University, Thomas Jefferson University and King’s College London.